These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 15940851)

  • 1. Lessons from expanded government enforcement efforts against drug companies.
    Scheineson MJ; Klinger ST
    Food Drug Law J; 2005; 60(1):1-16. PubMed ID: 15940851
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary on payment and reimbursement issues affecting the marketing of drugs, medical devices, and biologics, with emphasis on the anti-kickback statute and Stark II.
    Reiss JB
    Food Drug Law J; 1997; 52(1):99-108. PubMed ID: 10346713
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug marketing from an Office of Inspector General enforcement perspective.
    Foley LA
    Food Drug Law J; 1995; 50(2):309-12. PubMed ID: 10342999
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent multistate enforcement initiatives: prescription drug promotional practices.
    Woodward D
    Food Drug Law J; 1995; 50(2):295-300. PubMed ID: 10342997
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceutical marketing practices: balancing public health and law enforcement interests; moving beyond regulation-through-litigation.
    Zalesky CD
    J Health Law; 2006; 39(2):235-64. PubMed ID: 17002233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding government regulation of the marketing and advertising of medical devices, drugs, and biologics: the challenges of the Internet.
    Reichertz PS
    Food Drug Law J; 1997; 52(3):303-8. PubMed ID: 10343029
    [No Abstract]   [Full Text] [Related]  

  • 7. Prescription drug advertising--should states regulate what is false and misleading?
    Shaeffer J
    Food Drug Law J; 2003; 58(4):629-48. PubMed ID: 15027454
    [No Abstract]   [Full Text] [Related]  

  • 8. Kickbacks, courtesies or cost-effectiveness?: Application of the Medicare antikickback Law to the marketing and promotional practices of drug and medical device manufacturers.
    Bulleit TN; Krause JH
    Food Drug Law J; 1999; 54(3):279-323. PubMed ID: 11797701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FTC monitors health industry for misleading, deceptive ads.
    Daynard M
    Rev Fed Am Health Syst; 1987; 20(4):29. PubMed ID: 10282868
    [No Abstract]   [Full Text] [Related]  

  • 10. Enforcement actions involving Medicaid fraud and abuse, 1996-2009.
    Qureshi ZP; Liu Y; Sartor O; Chu YH; Bennett CL
    Arch Intern Med; 2011 Apr; 171(8):785-7. PubMed ID: 21518950
    [No Abstract]   [Full Text] [Related]  

  • 11. [Drug counterfeiting and counter measures. Study by the Hungarian National Alliance Against Drug Counterfeiting].
    Psychiatr Hung; 2009; 24(3):205-14. PubMed ID: 20017282
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceuticals and medical devices: business practices. End-of-year issue brief.
    Jones TM
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-32. PubMed ID: 18345554
    [No Abstract]   [Full Text] [Related]  

  • 13. A patient's right of privacy in computerized pharmacy records.
    Mowery G
    Univ Cincinnati Law Rev; 1998; 66(2):697-746. PubMed ID: 16211743
    [No Abstract]   [Full Text] [Related]  

  • 14. Industry probe. Justice Department subpoenas dialysis providers.
    Mantone J
    Mod Healthc; 2004 Nov; 34(44):17. PubMed ID: 15554339
    [No Abstract]   [Full Text] [Related]  

  • 15. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 16. Just what the doctor ordered: avoiding kickback pitfalls with prescription drugs.
    Simmer WS
    Manag Care Interface; 2002 Jan; 15(1):90-2. PubMed ID: 11828611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary wholesalers oppose FDA pedigree regulation.
    Young D
    Am J Health Syst Pharm; 2001 Sep; 58(18):1698, 1700. PubMed ID: 11571811
    [No Abstract]   [Full Text] [Related]  

  • 18. Finding money for health care reform--rooting out waste, fraud, and abuse.
    Iglehart JK
    N Engl J Med; 2009 Jul; 361(3):229-31. PubMed ID: 19516025
    [No Abstract]   [Full Text] [Related]  

  • 19. Canadian health ministry is given new powers to tighten drug safety.
    Dyer O
    BMJ; 2014 Jun; 348():g4231. PubMed ID: 24962373
    [No Abstract]   [Full Text] [Related]  

  • 20. US drug companies paid $15bn in fines for fraudulent marketing in past five years.
    Tanne JH
    BMJ; 2010 Dec; 341():c7360. PubMed ID: 21177361
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.